Rectal Cancer - Pipeline Review, H2 2018 Featuring AbbVie, Amgen, Eisai, Eli Lilly, Merck, and more - ResearchAndMarkets.com
The "Rectal Cancer - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.Rectal Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 2, 1, 1 and 1 respectively.
Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- AbbVie Inc.
- Advaxis Inc.
- Amgen Inc.
- Eisai Co. Ltd.
- Eli Lilly and Co.
- Incyte Corp.
- Merck KGaA
- NewLink Genetics Corp.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xrdzmq/rectal_cancer?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181019005179/en/